

MEDTECH & PHARMA PLATFORM ASSOCIATION (MPP)

Activities & Outlook - December 2022

Looking back at 2022

Throughout the year, the MPP engaged in various activities to increase synergies between the medtech, pharma and tech industries and promote the development of innovative combined products.



Policy monitoring and evaluation

The MPP members exchanged on and assessed legislative and regulatory developments for combined products. Discussions focused on topics such as the MDR implementation, risk management and cybersecurity for connected combined products and platform technologies. The MPP outlined reflections on the current regulatory framework for connected combined products and their development, including usability and human factor engineering, in a [paper](#) published in *Clinical Therapeutics* in April 2022.



Engagement with decision-makers and stakeholders

The MPP members and Secretariat voiced the MPP position and discussed the pharma, medtech and data frameworks at a diversity of events held by the European Medicines Agency and with other stakeholders. The MPP shaped discussion on topics ranging from the centralized procedure to the use of big data in regulatory decision-making.



9th Annual Conference (8 September 2022)

The conference returned to an in-person format in 2022, with representatives from the industry, patient organizations, regulators and academia registered to benefit from the high-quality program and meet stakeholders and potential business partners. The panel, led by the MPP President, gathered speakers from the EU, US and Swiss regulatory agencies, notified bodies and the industry to exchange perspectives on the regulation of combined products. The thematic sessions shed light on key questions for combined products, including patient involvement and the development of digital health.



Webinar 'Early lessons on the developing regulatory framework for digital health and outlook on AI' (28 April 2022)

The webinar provided complementary perspectives from the industry and a notified body on the development and certification of health technologies involving digital components.

Outlook for 2023

The MPP will carry on its activities to address the challenges raised by the development of combined products and better integrate them in the regulatory framework:

- **Foster cross-industry exchanges:** For the MPP, experience sharing and networking are essential to identify the hurdles, discuss best practices and define potential solutions. The 10-year anniversary edition of the Annual Conference will take place on **27 September 2023** in Basel, Switzerland.

MEDTECH & PHARMA PLATFORM

- Engage in dialogue with key stakeholders: A common understanding of the challenges for combined products and the necessary legislative and regulatory adjustments is key to improve the framework for the development of these products in the EU. The MPP remains committed to promote dialogue with regulators, decision makers and other stakeholders to find practical solutions for combined products.
- Assess the legislative and regulatory developments: Our working groups on combined products and connected combined products will closely monitor the initiatives relevant for combined products, including with the upcoming revision of the EU pharmaceutical legislation.

MPP members



Join the MPP

Learn more about the MPP and how to join us [on our website](#) or contact the MPP Secretariat.

Medtech & Pharma Platform

c/o SFL Regulatory Affairs & Scientific Communication GmbH

Aeschenvorstadt 52

CH-4051 Basel I Schweiz

+41 61 361 9443

association@medtech-pharma.com

<https://medtech-pharma.com/>



[Medtech & Pharma Platform Association](#)